Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Lumos Networks Appoints Timothy Biltz As CEO - Quick Facts

RELATED NEWS
Trade LMOS now with 

Lumos Networks Corp. (LMOS: Quote) announced that it appointed Timothy Biltz as its Chief Executive Officer, effective April 26, 2012. The company said that Biltz replaces James Hyde who has been serving as the interim Chief Executive Officer following the separation from NTELOS Holdings Corp. in October 2011. Hyde will remain in his position as a member of the Lumos Networks Board of Directors.

Biltz served as Chairman of the Board of Directors of iPCS, Inc. from November 2006 through December 2009. From 1999 to 2005, Biltz was the Chief Operating Officer of SpectraSite, Inc. From 1989 to 1999, Biltz was employed by Vanguard Cellular Systems, Inc. in a number of posts of increasing responsibility, ultimately serving as the Executive Vice President and Chief Operating Officer.

Lumos Networks also announced that Michael Moneymaker is retiring from his position as President of Lumos Networks and as a member of the Board of Directors.

In connection with Biltz's appointment, Lumos Networks granted Biltz certain equity awards, including 165,000 shares of restricted stock.

The restricted stock will vest in four annual installments beginning December 31, 2012 and ending December 31, 2014.

The company said its board declared a quarterly cash dividend on its common stock in the amount of $0.14 per share to be paid on July 12, 2012 to stockholders of record on June 14, 2012.

Register
To receive FREE breaking news email alerts for Lumos Networks Corp. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Micro-blogging site Twitter Inc said Tuesday after the markets closed that its second quarter loss widened from last year, hurt mainly by stock-based compensation expense, even as revenue more than doubled thanks to growth in advertising. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue. Pharmaceutical giant Pfizer, Inc., which was aspiring to buy British drug maker AstraZeneca Plc, reported Tuesday a profit for the second quarter that plunged 79 percent from last year, which reflected hefty gains from animal health business sales. Total revenues declined 2 percent, as it continued to be hurt by generic competition for major drugs. Home improvement and building products company Masco Corp. said Monday after the markets closed that its second quarter profit jumped 78% from last year, as revenue increased and margins improved amid strong performance of its Plumbing Products, Installation and Other Services and Decorative Architectural Products segments.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.